Search company, investor...
Can-Fite BioPharma company logo

Can-Fite BioPharma


Other Investors | Alive



About Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

Headquarters Location

10 Bareket Street Kiryat Matalon

Petach-Tikva, 49170,


+972 3 9241114

Missing: Can-Fite BioPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Can-Fite BioPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Can-Fite BioPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Can-Fite BioPharma is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest Can-Fite BioPharma News

Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment

Jan 19, 2021

{{following ? "Following" : "Follow"}} Advertiser Disclosure The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content that follows is for informational purposes only and not intended to be investing advice. January 19, 2021 1:26pm  796  Comments Share: Can-Fite Biopharma  Ltd. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. In the era of constant development and innovation, there is still a lot to learn about the human body and how certain diseases develop. Without a doubt, 2020 marked the race to find an effective vaccine against COVID-19. However, this is not the only focus of the medical field; treatments for cancer and auto-immune diseases such as psoriasis are a priority to boost and improve our quality of life. Can-Fite Biopharma Ltd. (NYSE: CANF ) — a company that focuses on treating inflammatory, cancer, and metabolic diseases through its technological platform — understands that the current pandemic can aggravate certain conditions or make patients more vulnerable. Thus, making offering innovative therapies a priority to get substantial medicinal outcomes. Can-Fite’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for moderate-to-severe psoriasis and a Phase II study to treat moderate COVID-19. Lead Drug Candidate Piclidenoson Piclidenoson has been dosed in over 1,500 patients with an excellent safety profile in clinical trials to date. In contrast, the biologics on the market approved to treat psoriasis have black box warnings with many listed side-effects. While psoriasis is a severe disease with quality of life implications for patients, it is not life-threatening. Therefore, patients recognize that while they need effective treatment, safety is also a high priority. The Company’s technology platform findings help provide targeted therapy, mainly aimed at the diseased cells, thus not harming normal body cells and tissues and reducing potential risks. Can-Fite’s lead drug candidate offers several potential key benefits over psoriasis treatments currently on the market. It provides easy administration for patients who tend to prefer oral medications over injectables as an oral pill. A 2018 study on psoriasis patient preferences published in American Health & Drug Benefits showed the two most important considerations for choosing a psoriasis drug were the route of administration and cost, with oral administration and lower cost being most preferred. Currently, major players in the psoriasis marker are AbbVie (NYSE: ABBV ), Amgen (NASDAQ: AMGN ), Johnson & Johnson (NASDAQ: JNJ ), Bristol-Myers Squibb Company (NYSE: BMY ), Novartis (NYSE: NVS ),  and Pfizer Inc. (NYSE: PFE ), among others. The drugs compared to Piclidenoson are Humira®, Enbrel®, Remicade®, and Otezla®. The World Of Psoriasis  According to , psoriasis is an immune-mediated disease with an unclear cause characterized by chronic inflammation caused by the immune system's dysfunction. Some visible signs are raised plaques and scales on the skin, commonly located on the scalp, trunk, and extensor surfaces. According to the World Psoriasis Day consortium , 125 million people worldwide have psoriasis—2 to 3 percent of the total population. In fact, patients with this disease experience a tremendous negative impac t on their quality of life, including high rates of comorbidities, including cardiovascular disease, psoriatic arthritis, Crohn's disease, obesity, type II diabetes mellitus, metabolic syndrome, and depression, among others. Besides, this disease has far-reach psychosocial implications in some patients. It is also essential to notice that patients with psoriasis have high annual health costs compared to others in the population. The market size for psoriasis is estimated to be $11.5 billion at the end of 2020 . Can-Fite Study  The Comfort™ Phase III psoriasis study is designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority than Apremilast (Otezla®) in patients with moderate to severe plaque psoriasis. The randomized, double-blind study is being conducted in Europe, Israel, and Canada. Prior studies of Piclidenoson in psoriasis: A Phase II study in psoriasis successfully met its primary endpoint showing that Piclidenoson effectively ameliorates disease symptoms. In the Phase II/III study, the data showed clinical activity from week 16 till 32. About Can-Fite Biopharma Can-Fite BioPharma Ltd. is an Israeli clinical-stage drug development company with a platform technology that is designed to address the treatment of cancer, liver, inflammatory disease, and COVID-19. In addition, the company has an advanced pipeline of proprietary compounds in phase II and III clinical development stage. Its drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. The company currently has an intellectual property portfolio of 15 patent families issued and pending to protect the different indications. Corporate partnerships for Piclidenoson and Namodenoson out-licensed in select territories with ~$18 million received to date; the company is well-positioned to conduct all its clinical development programs and G&A for > 1 year.

Can-Fite BioPharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Can-Fite BioPharma Rank

Can-Fite BioPharma Frequently Asked Questions (FAQ)

  • Where is Can-Fite BioPharma's headquarters?

    Can-Fite BioPharma's headquarters is located at 10 Bareket Street, Petach-Tikva.

  • What is Can-Fite BioPharma's latest funding round?

    Can-Fite BioPharma's latest funding round is Other Investors.

  • Who are the investors of Can-Fite BioPharma?

    Investors of Can-Fite BioPharma include Giza Venture Capital.

  • Who are Can-Fite BioPharma's competitors?

    Competitors of Can-Fite BioPharma include Evotec SE, Arena Pharmaceuticals, ISA Pharmaceuticals, Ardelyx, Hydra Biosciences, Acetylon Pharmaceuticals, Marinus Pharmaceuticals, GlycoMimetics, Mimetogen Pharmaceuticals, Micromet and 19 more.

Compare Can-Fite BioPharma to Competitors


MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

United Biomedical

United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.